Focus Group on BCS (Biopharmaceutics Classification System) and Biowaiver

Chair: Prof. Jennifer Dressman

BCS and Biowaivers is a Focus Group that belongs to the Special Interest Group on Regulatory Sciences.


  • Provide a worldwide and independent platform for scientific discussion among academia, industry and regulators on the possibilities and the limitations of biowaivers for in vivo bioequivalence studies. 
  • Stimulate development of new biowaver methods.




In constant memory of: Dirk Barends, Founder of the Focus Group

Please click here to view a short tribute to Dirk Barends and his contributions to the Focus Group


Biowaiver monographs

Biowaiver monographs are literature reviews, in which publicly available data are gathered and organized to address the question of whether a biowaiver can be recommended for a new formulation of that API. Parameters and points discussed are: solubility and permeability, dissolution of dosage forms, pharmacokinetics, the therapeutic use and therapeutic window of the API, data on excipient interactions and problems with bioavailability and/or bioequivalence. For more information and a list of available monographs: click here.


Sharing expertise with Regulatory agencies

The SIG on BCS & Biowaivers reviewed and commented on the following draft guidelines:

With Health Canada:
Our comments (click here) on the draft guidelines Conduct and Analysis of Comparative Bioavailability Studies (click here) and Comparative Bioavailability Standards: Formulations used for Systemic Effects (click here).


Important International Regulatory documents

For an overview of links to important international regulatory documents, click here



International Workshop on Implementation of Biowaivers based on the Biopharmaceutics Classification System (BCS) (5 & 6 March 2015)

Please click on the report for more information.


International Symposium on Bioequivalence (August 2012)

An International Symposium on Bioequivalence was held in August 2012 in Thailand. Please click on the report for more information.


The Global Bioequivalence Harmonisation Initiative (GBHI) 2nd Conference is now fixed to September 15-16, 2016, Washington DC USA.

Initiated by the EUFEPS Bioavailability and Biopharmaceutics Network, it will be organised by EUFEPS and AAPS in collaboration – following on the successful GBHI 1st Conference held in 2015 in Amsterdam NL. For scope and aim, preliminary programme, speakers and other contributors to it, and registration and accommodation information, see the GBHI Conference site e.g. at: which will be up running soon.


Interested in organizing a workshop with support from FIP & and the SIG BCS?
Contact the FIP Scientific Secretary Prof. Giovanni Pauletti via



Peter Langguth & Marlies Kubbinga run BIOTHREE, carried out at the Dutch National Institute for Public Health and the Environment (RIVM) and the Johannes Gutenberg University of Mainz, and co-sponsored by the Pharmaceutical Quality Research Institute (PQRI) and the FIP, to develop a comparative in vitro permeability test, to become a second surrogate in vitro bioequivalence test, in addition to comparative in vitro dissolution testing.

Several members of the Focus group participate in a European initiative to streamline pharmaceutical development. A link to this pan-European research project can be found under